Bydureon is the first and only once-weekly treatment for type 2 diabetes. It was approved by the US FDA on January 27th 2012 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The approval was based on safety and efficacy data from the DURATION clinical trial program, in which treatment with Bydureon resulted in improvements in glycemic control in a once-weekly dose.
Bydureon is provided in a straightforward single-dose tray so that patients can self-administer the once-weekly subcutaneous injection. To help patients get off to a successful start, Amylin offers Bydureon Steady Support for patients and healthcare providers. Bydureon Steady Support offerings include flexible resources for healthcare providers and their patients to learn about Bydureon, how to administer it and how to sign up to receive ongoing support to help manage type 2 diabetes. This support will include access to Bydureon specialists seven days a week via a toll-free number, interactive tutorials online and the opportunity to schedule in-person training sessions with a diabetes educator.
Amylin says it is committed to assisting patients with diabetes in accessing coverage for Bydureon. Eligible patients will have access to the Bydureon Steady Savings Card to help offset copay costs. With the Steady Savings Card, these patients can save up to $50 per month on Bydureon prescriptions for up to 24 months. A patient assistance program is also available for eligible patients who have been prescribed Bydureon but do not have insurance for prescription drugs. Additional information can be found at www.bydureonreimbursement.com.